Monomeric C-Reactive Protein: Current Perspectives for Utilization and Inclusion as a Prognostic Indicator and Therapeutic Target
Monomeric C-reactive protein (mCRP), once thought to be a figment of the imagination and whose biological activity was ascribed to its sodium azide preservative, has now pronounced itself as a critical molecule playing a direct role in mediating many of the acute and chronic aberrant pathological re...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-03-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.866379/full |
| _version_ | 1818910003567788032 |
|---|---|
| author | Mark Slevin Mark Slevin Mark Slevin Nima Heidari Nima Heidari Leonard Azamfirei |
| author_facet | Mark Slevin Mark Slevin Mark Slevin Nima Heidari Nima Heidari Leonard Azamfirei |
| author_sort | Mark Slevin |
| collection | DOAJ |
| description | Monomeric C-reactive protein (mCRP), once thought to be a figment of the imagination and whose biological activity was ascribed to its sodium azide preservative, has now pronounced itself as a critical molecule playing a direct role in mediating many of the acute and chronic aberrant pathological responses to inflammation. In this focused mini review, we describe the currently attributed pathobiological interactions of mCRP in disease, where its tissue and cellular distribution and deposition have recently been clearly characterized and linked to inflammation and other pathway-associated progression of neurological and cardiovascular complications and deleterious outcomes. and focus upon current opinions as to the diagnostic and prognostic potential of mCRP-plasma circulating protein and define the possible future therapeutics including ongoing research attempting to block CRP dissociation with small molecule inhibitors or prevention of cell surface binding directly using antibodies or modified orphan drug targeting directed towards CRP, inhibiting its cellular interactions and signaling activation. There is no doubt that understanding the full influence of the biological power of mCRP in disease development and outcome will be considered a critical parameter in future stratified treatment. |
| first_indexed | 2024-12-19T22:35:54Z |
| format | Article |
| id | doaj.art-78097a3fe9f24f96911c6047589a747b |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-19T22:35:54Z |
| publishDate | 2022-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-78097a3fe9f24f96911c6047589a747b2022-12-21T20:03:12ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-03-011310.3389/fimmu.2022.866379866379Monomeric C-Reactive Protein: Current Perspectives for Utilization and Inclusion as a Prognostic Indicator and Therapeutic TargetMark Slevin0Mark Slevin1Mark Slevin2Nima Heidari3Nima Heidari4Leonard Azamfirei5Department of Life Sciences, George Emil Palade University of Medicine, Pharmacy, Science and Technology, Targu Mures, RomaniaThe Regenerative Clinic, London, United KingdomThe School of Life Sciences, Manchester Metropolitan University, Manchester, United KingdomDepartment of Life Sciences, George Emil Palade University of Medicine, Pharmacy, Science and Technology, Targu Mures, RomaniaThe Regenerative Clinic, London, United KingdomDepartment of Life Sciences, George Emil Palade University of Medicine, Pharmacy, Science and Technology, Targu Mures, RomaniaMonomeric C-reactive protein (mCRP), once thought to be a figment of the imagination and whose biological activity was ascribed to its sodium azide preservative, has now pronounced itself as a critical molecule playing a direct role in mediating many of the acute and chronic aberrant pathological responses to inflammation. In this focused mini review, we describe the currently attributed pathobiological interactions of mCRP in disease, where its tissue and cellular distribution and deposition have recently been clearly characterized and linked to inflammation and other pathway-associated progression of neurological and cardiovascular complications and deleterious outcomes. and focus upon current opinions as to the diagnostic and prognostic potential of mCRP-plasma circulating protein and define the possible future therapeutics including ongoing research attempting to block CRP dissociation with small molecule inhibitors or prevention of cell surface binding directly using antibodies or modified orphan drug targeting directed towards CRP, inhibiting its cellular interactions and signaling activation. There is no doubt that understanding the full influence of the biological power of mCRP in disease development and outcome will be considered a critical parameter in future stratified treatment.https://www.frontiersin.org/articles/10.3389/fimmu.2022.866379/fullmonomeric C-reactive proteindiagnostictherapeuticcardiovascular diseaseneuropathology |
| spellingShingle | Mark Slevin Mark Slevin Mark Slevin Nima Heidari Nima Heidari Leonard Azamfirei Monomeric C-Reactive Protein: Current Perspectives for Utilization and Inclusion as a Prognostic Indicator and Therapeutic Target Frontiers in Immunology monomeric C-reactive protein diagnostic therapeutic cardiovascular disease neuropathology |
| title | Monomeric C-Reactive Protein: Current Perspectives for Utilization and Inclusion as a Prognostic Indicator and Therapeutic Target |
| title_full | Monomeric C-Reactive Protein: Current Perspectives for Utilization and Inclusion as a Prognostic Indicator and Therapeutic Target |
| title_fullStr | Monomeric C-Reactive Protein: Current Perspectives for Utilization and Inclusion as a Prognostic Indicator and Therapeutic Target |
| title_full_unstemmed | Monomeric C-Reactive Protein: Current Perspectives for Utilization and Inclusion as a Prognostic Indicator and Therapeutic Target |
| title_short | Monomeric C-Reactive Protein: Current Perspectives for Utilization and Inclusion as a Prognostic Indicator and Therapeutic Target |
| title_sort | monomeric c reactive protein current perspectives for utilization and inclusion as a prognostic indicator and therapeutic target |
| topic | monomeric C-reactive protein diagnostic therapeutic cardiovascular disease neuropathology |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.866379/full |
| work_keys_str_mv | AT markslevin monomericcreactiveproteincurrentperspectivesforutilizationandinclusionasaprognosticindicatorandtherapeutictarget AT markslevin monomericcreactiveproteincurrentperspectivesforutilizationandinclusionasaprognosticindicatorandtherapeutictarget AT markslevin monomericcreactiveproteincurrentperspectivesforutilizationandinclusionasaprognosticindicatorandtherapeutictarget AT nimaheidari monomericcreactiveproteincurrentperspectivesforutilizationandinclusionasaprognosticindicatorandtherapeutictarget AT nimaheidari monomericcreactiveproteincurrentperspectivesforutilizationandinclusionasaprognosticindicatorandtherapeutictarget AT leonardazamfirei monomericcreactiveproteincurrentperspectivesforutilizationandinclusionasaprognosticindicatorandtherapeutictarget |